Shenzhen Chipscreen Biosciences News

Microchip Biotech (688321): Rapid sales growth and innovation pipeline actively promoted

Aug 28 19:11

Microchip Biotech (688321): Continued development of new indications for sidabendamide and siglitazide entering the harvest period

Aug 19 00:00

Microchip Biotech (688321): Significant cost reduction and efficiency gains will soon usher in the DLBCL harvest period

Aug 17 00:00

Microchip Biotech (688321): Steady business performance and continuous promotion of core products

Aug 16 00:00

Microchip Biotech (688321): The expansion of the original innovative drug with multiple indications is expected to embark on a new journey of internationalization

Jul 19 00:00

Microchip Biotech (688321): Cidabendamide's colorectal cancer indications to be included in breakthrough treatments are expected to open up market space

Jun 6 07:32

Microchip Biotech (688321): Big Indications Drive High Growth, Cash Flow Turns Losses into Profits

May 10 13:46

Microchip Biotech (688321): It is expected to usher in multiple inflection points in valuation+performance+data in 24

Apr 29 00:00

Microchip Biotech (688321): 2024 enters the harvest year of Microchip's innovative drugs

Apr 22 00:00

Microchip Biotech (688321): 2024 enters the harvest year of Microchip's innovative drugs

Apr 19 16:16

Huafu Securities released a research report on April 18 stating that it gave Microchip Biotech (688321.SH) a purchase rating. The main reasons for the rating include: 1) the sales peak for sidabendamide hematomas is expected to exceed 1 billion dollars, a

Zhitong FinanceApr 18 16:56

Microchip Biology (688321): Sidabenamide is making a comeback with great potential for treating solid tumors

Apr 18 15:41

Microchip Biotech (688321): Expecting siglitat sodium dosage and cidabenamide DLBCL data

海通證券Aug 22, 2023 07:32

Microchip Biotech (688321): Revenue from two core products is growing steadily, and new indications have been accepted

興業證券Aug 17, 2023 17:06

Microchip Biotech (688321) Company's Dynamic Review: Sighlitazol successfully passed the National Conference Multi-Pipeline and clinical progress was progressing smoothly

長城證券Feb 3, 2023 00:00

Microchip Biotech (688321): Two major indications with strong revenue resilience under the pandemic Phase III enrollment completed

海通證券Aug 27, 2022 00:00

Microchip Biology (688321): High revenue growth, Sioroni small cell lung cancer clinical trial launched in the US

海通證券Apr 8, 2022 07:57

Microchip Biotech (688321) Company Follow-up Report: Pioneer Pipelines for Pioneer Drugs in China Are Gradually Abundant

興業證券Apr 4, 2022 00:00

Microchip Biotech (688321) 2021 Interim Report Performance Review: Revenue Growth Meets Expectations, Two Core Varieties Are Expected to Continue to Show Remarkable Performance

國海證券Aug 29, 2021 00:00

Microchip Biotech (688321): Revenue growth far exceeded expectations, and two core varieties ushered in an accelerated release period

國海證券Apr 30, 2021 00:00